Ornitop

Quick links to important sections

Ornitop

Method of action: Antiprotozoal

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ornitop

Quick Facts

Property Description
Active Ingredient Ornidazole
Forms Film-coated tablets, solution for infusion, vaginal suppositories
Pharmacological Class Antiprotozoal and Antibacterial Agent
General Purpose Management of protozoal and anaerobic bacterial infections
Origin Synthetic Compound (Nitroimidazole Derivative)

Ornitop is a potent anti-infective medicine centered on the synthetic compound Ornidazole, designed to manage health conditions caused by susceptible microorganisms. This drug belongs to the nitroimidazole derivative family, a specific pharmacological class known for its focused effectiveness against certain parasites and bacteria. Ornidazole exerts a rapid, concentration-dependent microbial killing effect.


What Type of Medicine is Ornitop? (Identity and Classification)

Ornitop is an antimicrobial drug categorized primarily as an Antiprotozoal and Antibacterial Agent. Its foundation is the active ingredient Ornidazole, a synthetic compound that is chemically a 5-nitroimidazole derivative. The drug's efficacy is recognized for its targeted action. Ornidazole is identified by the ATC code P01AB03, grouping it with other nitroimidazole derivatives used against protozoal diseases. This establishes the drug's specialized role within the global pharmaceutical identity.


Active Ingredient, Composition, and Available Forms

The core composition of the medicine is a single-component product containing only the active pharmaceutical ingredient Ornidazole. This specific formulation differentiates it from combination therapies and emphasizes its use as a dedicated anti-infective agent. To allow for diverse delivery, the medicine is manufactured in multiple pharmaceutical preparations, including film-coated tablets for oral use, a sterile solution for infusion for intravenous (systemic) delivery, and specialized vaginal suppositories for local treatment. This wide range of high-level dosage forms ensures the active substance can be applied appropriately, whether systemically via the bloodstream or localized.


General Purpose and Anti-Infective Utility

The general purpose of Ornidazole is to act as a potent parasitotropic and bactericidal agent for the elimination of susceptible organisms. This compound is used to address the microbial presence responsible for certain protozoal infections and specific anaerobic bacterial infections. The drug achieves its effect through a mechanism of selective toxicity, targeting the unique biological processes of the invading microbes. The utility is therefore precise: to resolve health conditions where these particular types of pathogens are identified as the causative agents.

What side effects are possible with Ornitop?

Possible side effects and safety information

The safety profile of Ornidazole is structured by regulatory authorities based on officially documented adverse reactions and specific constraints. Side effects are classified by frequency and grouped into System-Organ Classes (SOCs), with effects on the Nervous System and Gastrointestinal System being the most frequently classified groups.

Frequency-Classified Adverse Reactions

Adverse reactions classified as Uncommon often involve the digestive tract, such as nausea, vomiting, diarrhea, and epigastric discomfort. Reactions classified as Very Rare include more significant neurological effects like headache, dizziness, tremor, and sensory or mixed peripheral neuropathy. Specific effects, such as anaphylaxis or confusion, have a Not Known frequency, meaning incidence cannot be estimated from available data.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight potentially serious reactions, including Seizures, Psychotic Reactions, and severe, persistent Peripheral Neuropathy, which is associated with longer duration of treatment. The medicine is contraindicated in patients with known hypersensitivity to Ornidazole or other nitroimidazole derivatives.

Furthermore, official labeling states that alcohol must not be consumed during treatment and for a period of at least 3 days after discontinuation due to the risk of a severe disulfiram-like reaction. Caution is also advised for patients with pre-existing Hepatic Impairment (liver disease) or Central Nervous System (CNS) diseases.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents outline the specific signs and actions required in the event of an Ornidazole overdose.

Documented Overdose Manifestations

System Affected Official Regulatory Statements
Central Nervous System Overdose may present with somnolence, headache, vertigo, cramps, and potentially loss of consciousness [Source 1.2, 2.5].
Gastrointestinal Overdosage can cause gastrointestinal disturbances (including nausea and vomiting) that manifest in a more severe form [Source 1.2].
Cardiovascular The potential for QT interval prolongation is noted, which necessitates ECG monitoring in a clinical setting [Source 1.2].

Required Emergency Actions

The regulator-mandated guidance requires that individuals seek urgent medical attention immediately for any suspected overdose [Source 1.3]. This action involves contacting a doctor or National Poisons Information Centre, or proceeding to the nearest Accident and Emergency Centre [Source 1.3]. This step is explicitly required even if there are no immediate signs of discomfort or poisoning [Source 1.3].

In terms of management, no specific antidote is known for Ornidazole overdose [Source 1.2, 2.5]. Management is restricted to symptomatic and supportive treatment, with the official recommendation being the administration of diazepam for the control of cramps [Source 1.2, 2.5]. Hospital observation, including ECG monitoring, is necessary for severe cases due to the documented risk of cardiac effects [Source 1.2].

Therapeutic Uses of Ornitop

What Ornitop Treats: Main Uses and Benefits

Ornitop is commonly used across domains where additional symptomatic support is needed in conditions presenting with acute or disruptive symptom patterns. The medicine is relevant for addressing conditions like Protozoal Infections, such as Amoebiasis, Giardiasis, and Trichomoniasis, as well as various Anaerobic Bacterial Infections affecting the gastrointestinal, uro-genital, and dental regions.

In clinical settings that involve acute or unstable symptom patterns, the medication assists with easing symptom clusters that may become intense or disruptive, such as severe gastrointestinal distress or localized pain and swelling associated with infections like pericoronitis. This treatment helps maintain a sense of stability when symptoms are more noticeable.


“Applied during phases when symptoms become more noticeable, this medicine supports patients during difficult episodes by easing distress.”


Ornitop is also applied in clinical settings for surgical prophylaxis, where it is used pre-operatively to reduce the risk of serious infectious complications following certain procedures. This supportive measure assists with maintaining functional stability.

Quick Fact: Support for Localized Discomfort
Symptom Axis: Symptoms related to inflammatory or irritative states
Clinical Focus: Conditions presenting with systemic or localized discomfort
Patient Benefit: Assists with maintaining functional stability and comfort

Regulatory References

  1. official New Zealand Medsafe data sheet

Eligibility and Restrictions for Use

The eligibility for using Ornitop is strictly defined by official regulatory labeling, which outlines populations who are contraindicated or require conditional use.

Contraindications and Restrictions

Classification Population Group Condition/Status
Absolute Contraindication Hypersensitivity Known allergy to ornidazole or other nitroimidazole derivatives (e.g., metronidazole) [Source 1.6]
Absolute Contraindication CNS Disorders Presence of central nervous system disorders, particularly epilepsy or peripheral neuropathy [Source 1.5]
Absolute Contraindication Pregnancy Use during the first trimester of pregnancy [Source 1.6]
Restricted Use (Caution) Hepatic Impairment Severe hepatic impairment requires the dosing interval to be doubled [Source 1.1]
Not Recommended Lactation Nursing (breastfeeding) mothers, unless deemed absolutely necessary [Source 1.6]
Conditional Eligibility Renal Impairment Dose adjustment is unnecessary as the drug's pharmacokinetics are unaltered by impaired renal function [Source 3.2]
Age-Related Rule Pediatric Use is permitted in children but is contraindicated in infants with a body mass under 6 kg [Source 1.1]

Official labeling mandates caution for patients with a history of blood disorders or those with multiple sclerosis [Source 1.1, 1.6]. Adults are the general population for approved use, and sexual partners may be treated concurrently for specific infections.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ornitop (Ornidazole) has officially documented interaction patterns primarily categorized as Metabolic Clearance Modulation, Pharmacodynamic Potentiation, and Substance Restriction. These patterns are defined by regulatory authorities to ensure precise administration.

Documented Interaction Patterns

Interacting Medicine or Substance Official Interaction Outcome Timing and Use Restrictions
Alcohol Contraindicated; Strict Prohibition Must not be ingested during therapy or for at least 3 days after the final dose.
Coumarin Anticoagulants (e.g., Warfarin) Potentiation of the anticoagulant effect. Requires more frequent monitoring of the International Normalized Ratio (INR).
Vecuronium bromide Prolongs the muscle-relaxant effect. Official regulatory caution due to additive pharmacodynamic effect.
Cimetidine May decrease Ornidazole plasma clearance. Prolongs the elimination half-life of Ornidazole.
Phenobarbital / Phenytoin May reduce Ornidazole half-life. Potential for decreased systemic exposure to Ornidazole.
Lithium May increase plasma levels of Lithium. Requires more frequent monitoring of Lithium concentrations.

This interaction structure establishes that co-administration of Ornidazole with certain medicines or substances can formally alter the concentration of either drug, or produce additive effects. The regulatory profile specifically restricts co-use with alcohol and details how clearance-modifying agents and anticoagulants interact.

Mechanism of Action

Selective Activation and Toxicity Gatekeeping

The mechanism relies on selective toxicity, initiated by the drug acting as a prodrug that is only chemically activated within the unique, low-oxygen, reducing environment found inside susceptible anaerobic and microaerophilic pathogens. Microbial enzymes like oxidoreductases reduce the drug's nitro group, generating highly reactive and cytotoxic free radicals. This process acts as a gatekeeper, ensuring the toxin is produced primarily within the microbial target, which defines the drug's physiological action against the microbial target.


DNA Damage and Bactericidal Cascade

Once formed, the cytotoxic intermediates rapidly attack the pathogen's essential components, primarily causing irreversible strand breaks and fragmentation of Microbial DNA. This immediate and extensive damage halts the microbe's ability to replicate, repair, or transcribe genetic material, simultaneously disrupting anaerobic metabolism. The physiological consequence of this catastrophic molecular damage is a rapid and decisive bactericidal and protozoacidal effect, leading to the elimination of the susceptible organisms.


Oxygen as a Mechanistic Constraint

The efficacy of this mechanism is constrained by the presence of oxygen. Oxygen acts as a competing electron acceptor, which re-oxidizes the active toxic radical back into the inactive parent drug via a process known as "futile cycling." This chemical constraint prevents the formation of lethal metabolites in aerobic environments, biologically defining the narrow scope of the drug's anti-anaerobic spectrum of activity.

Dosage and Administration Information

How to Use Ornitop

Ornitop's administration follows specific parameters detailing the route, dosage, and duration of use. The medicine is available for oral administration as 500 mg film-coated tablets, for intravenous (IV) infusion in severe cases, and in specialized vaginal suppository forms for local application.


Standard Administration Patterns

The drug is prescribed for short, defined courses, typically ranging from a single dose up to 10 days. Standard adult dosing often follows a twice-daily (500 mg BID) schedule for maintenance therapy. Alternatively, for certain protozoal infections, there is a single high-dose regimen of 1.5 g to be taken once. When IV administration is necessary, it involves an initial loading dose of 0.5 g to 1.0 g, followed by 500 mg every 12 hours; the IV solution is diluted and infused slowly over 15 to 30 minutes.


Essential Use Conditions

Oral tablets are administered after meals to aid proper intake. If a dose is missed and it is nearly time for the next scheduled dose, it is typically recommended to skip the missed dose and not to take a double dose. For the treatment of trichomoniasis, the protocol involves the sexual partner being treated concomitantly with the same oral regimen.


Population-Specific Adjustments

Specific parameters exist for certain populations. In patients with severe hepatic impairment, the drug's elimination is slowed, which involves the dosing interval being doubled. Conversely, no dose adjustment is generally necessary for patients with renal impairment, though a supplemental dose is required following haemodialysis. Pediatric dosing is calculated by body weight, typically ranging from 25 mg/ kg to 40 mg/ kg per day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ornitop

Research Evidence for Protozoal Infections (Amoebiasis and Giardiasis)

Research focusing on Ornidazole was studied for protozoal diseases like Amoebiasis and Giardiasis primarily includes short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted to explore how the medicine was associated with Parasitological Cure (clearance of the organism) and Clinical Cure, which involved monitoring outcomes related to physical discomfort and changes measured during the study period related to acute symptoms. Findings describe patterns observed in the studies related to the rate of parasite clearance and the evolution of symptoms in the observed populations when Ornidazole was evaluated in comparative studies.

Research Evidence for Anaerobic Bacterial Infections

Research exploring Ornidazole was studied for infections caused by susceptible anaerobic bacteria is documented across regulatory summaries and clinical trials. These studies primarily monitored outcomes related to Bacteriological Clearance—the reduction or reported absence of the target organisms—and general measures of Clinical Efficacy Rate. Research examined adult patients with various types of infections. Data show patterns related to the changes measured during the study period of the infection over the short treatment window.

Evidence for Use in Pre-operative Surgical Prophylaxis

Specific RCTs and meta-analyses have been conducted to research examining Ornidazole was studied for surgical prophylaxis. These studies monitored outcomes related to preventing post-operative infectious complications, such as the incidence of Surgical Site Infection (SSI), typically assessed up to 30 days post-surgery. Research describes patterns observed was associated with the goal of preventing infection when was evaluated in this pre-operative context.


Unstudied Areas and Research Gaps

Despite the existing research, several areas of uncertainty and research gaps are noted in the scientific literature. The evidence quality varies across studies, with some older trials having modest sample sizes or methodological designs that do not determine high certainty. Long-term effects are not fully established and the rate of recurrence following the short-term course of treatment are not fully established across all indications. Data for specific populations, such as pregnant women or patients with complex health statuses, remain insufficient for comprehensive summaries.

Frequently Asked Questions (FAQ)

Common questions about Ornitop (FAQ)

Q: How long does it usually take to notice if Ornitop is working?

Regulatory studies indicate that the active ingredient in Ornitop exerts a rapid, concentration-dependent microbial killing effect on the target organisms. However, the time it takes to see evidence of clinical change in the condition can vary depending on the type and severity of the infection.

Q: Are the side effects of Ornitop generally considered mild?

Official information classifies many reported side effects, such as nausea, vomiting, or diarrhea, as Uncommon and typically non-serious. However, the regulatory label also explicitly warns of the potential for Very Rare but serious neurological adverse reactions, including seizures and severe, persistent peripheral neuropathy, especially with longer treatment durations.

Q: Can Ornitop cause problems with sleep?

Yes, official safety data lists both Somnolence (drowsiness) and Insomnia (difficulty sleeping) as possible, though generally rare, adverse reactions associated with the medication. These are noted as part of the potential effects on the nervous system.

Q: Does Ornitop interact with common over-the-counter pain relievers?

Regulatory interaction summaries primarily focus on specific prescription medications, such as certain anticoagulants and muscle relaxants. They do not typically list common over-the-counter pain relievers (like ibuprofen or acetaminophen) as having a formal interaction that requires a contraindication or dose adjustment.

Q: Are there any specific vitamins or supplements that should not be taken with Ornitop?

Official drug interaction tables list prescription drugs and alcohol as interacting substances. No specific vitamins or supplements are consistently listed as having a formal interaction, and the official documentation emphasizes the importance of sharing information about all products used.

Q: Can consuming caffeine affect how Ornitop works?

Caffeine is not listed in the official regulatory documents as an interacting substance that affects the absorption or effectiveness of Ornitop.

Q: Is Ornitop suitable for use in older adults (seniors)?

According to regulatory documents, no specific dose adjustment is typically required solely based on age for older adults. However, treatment requires caution and may necessitate dose adjustments if the patient has pre-existing liver or kidney impairment.

Q: Is it necessary to have certain tests before starting Ornitop?

Official labeling advises caution in patients with a history of blood disorders or those with Central Nervous System (CNS) diseases. While not always a general requirement, certain tests may be deemed necessary by a healthcare provider based on the patient's individual history, such as checks for hepatic impairment.

Q: Have there been many clinical trials conducted on Ornitop?

Regulatory summaries confirm that the drug has been investigated in short-term Randomized Controlled Trials (RCTs) and systematic reviews to explore its effectiveness for approved uses. The available research is documented, though official sources note that the evidence quality and sample sizes vary across some studies.

Q: Can Ornitop make you dizzy or affect your driving?

Regulatory labels list dizziness and vertigo as possible side effects. The official information contains a warning that the presence of these effects may impair a patient's ability to drive or operate machinery, and caution is advised.

Q: Does Ornitop have any known effects on weight?

Official regulatory documents and safety data generally do not list weight gain or weight loss among the documented common or uncommon adverse reactions for Ornitop.

Q: Why do some people experience stomach upset with Ornitop?

Gastrointestinal effects like nausea, vomiting, and epigastric discomfort are documented in safety summaries as adverse reactions commonly associated with the drug. To help mitigate these effects, the medication is officially instructed to be administered after meals.

Q: Can Ornitop be split or crushed, or must it be swallowed whole?

Ornitop tablets are typically film-coated and intended to be swallowed whole with a glass of water, usually after a meal. As with most film-coated medications, regulatory guidance does not generally advise splitting or crushing unless there is an explicit instruction to do so.

Q: If I stop taking Ornitop suddenly, what can I expect?

Ornitop is prescribed for a defined, short course of therapy to ensure complete elimination of the target organism. Completing the defined course is standard protocol to reduce the risk of treatment failure and recurrence of the original infection.

Q: Can taking Ornitop affect the results of lab tests?

Yes, official interaction data specifies that Ornitop may increase the effect of certain blood thinners (like Coumarin anticoagulants). This change requires more frequent monitoring of the International Normalized Ratio (INR), which is a common laboratory blood test.

Q: What should I do if the side effects of Ornitop feel worse than expected?

Regulatory safety documents state that severe adverse reactions, such as seizures or severe, persistent numbness or tingling, may necessitate immediate discontinuation of therapy. These are considered serious medical events requiring professional attention.

Q: Does Ornitop have an effect on blood pressure?

Changes in blood pressure are not listed among the commonly documented adverse reactions in the official regulatory summaries for Ornitop.

Q: Is there an increased risk of sun sensitivity while using Ornitop?

Increased sun sensitivity, also known as photosensitivity, is not listed among the officially documented skin or subcutaneous adverse reactions for Ornitop.

Q: Can Ornitop be used alongside other treatments for the same condition?

For specific infections like trichomoniasis, the regulatory protocol mandates the concomitant treatment of the sexual partner with the same regimen. Information regarding the co-administration of different types of medication for the same condition is managed by a healthcare professional.

Q: Can Ornitop be taken with a glass of milk?

The general regulatory instruction for oral tablets is that they must be administered after meals to aid proper intake. The official guidance does not contain any specific restriction against consuming milk or other common dairy products.

How should Ornitop be stored and disposed of?

How to Store and Dispose of Ornitop

Ornitop must be stored according to regulatory requirements to maintain its stability. Tablets should be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with protection from light and moisture. The medicine must remain in its original container and be stored out of the sight and reach of children to prevent accidental exposure.

Disposal

Unused or expired Ornitop should not be disposed of in household waste or via wastewater. Disposal must be performed in accordance with local requirements for unused medicinal products. Consult a healthcare professional or pharmacist for guidance on proper collection points.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ornitop found in:

A-Z Index: